Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.53 |
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29804768 | 0.81 | GPR84 (0.35) | OPRM1SLC6A2SLC6A4GPR84 | |
| SCHEMBL13085572 | 0.77 | CYP1A2 (0.45) | OPRM1HTR2AHTR2CDRD2SLC6A4 | |
| SCHEMBL30667253 | 0.75 | TSHR (0.38) | GPR84TSHR | |
| SCHEMBL27213000 | 0.75 | TSHR (0.38) | GPR84TSHR | |
| SCHEMBL30666538 | 0.72 | CRBN (0.40) | GPR84TSHR | |
| SCHEMBL27213006 | 0.72 | CRBN (0.40) | GPR84TSHR | |
| SCHEMBL2801416 | 0.72 | OPRM1 (0.41) | OPRM1 | |
| SCHEMBL30667240 | 0.71 | ESR1 (0.35) | GPR84 | |
| SCHEMBL29731975 | 0.70 | MEN1 (0.37) | OPRM1SLC6A4GPR84 | |
| SCHEMBL8819695 | 0.70 | OPRM1 (0.38) | OPRM1HTR2AHTR2CDRD2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206714-B1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8729264-B2 | Agent for prevention and/or treatment of skin diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-05-20 | — | — | US | disclosed |
| EP-1881014-B1 | ALPHA-OLEFIN/UNCONJUGATED CYCLIC POLYENE COPOLYMER, PROCESS FOR PRODUCING THE SAME, AND CROSSLINKABLE COMPOSITION CONTAINING THE COPOLYMER | MITSUI CHEMICALS INC (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2206714-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20090234073-A1 | Alpha-Olefin/non-conjugated cyclic polyene copolymers, production processes thereof, and crosslinkable compositions including the copolymer | MITSUI CHEMICALS, INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-7449475-B2 | Tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | disclosed |
| EP-1521757-B1 | TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | EP | disclosed |
| EP-1881014-A1 | -OLEFIN/UNCONJUGATED CYCLIC POLYENE COPOLYMER, PROCESS FOR PRODUCING THE SAME, AND CROSSLINKABLE COMPOSITION CONTAINING THE COPOLYMER | Mitsui Chemicals, Inc. (JP) | 2008-01-23 | — | — | EP | disclosed |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1586591-A1 | PROCESS FOR PRODUCING ETHYLENE/a-OLEFIN/UNCONJUGATED POLYENE COPOLYMER AND ETHYLENE/a-OLEFIN/UNCONJUGATED POLYENE COPOLYME R | Mitsui Chemicals, Inc. (JP) | 2005-10-19 | — | — | EP | disclosed |
| EP-1521757-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | REN, TACR1, AGTR1 | OPRM1 527/4885HTR2A 1174/4885HTR2C 1851/4885 |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | REN, TACR1, AGTR1 | OPRM1 627/4885HTR2A 1145/4885HTR2C 1811/4885 |
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | TYR, CUTA, SERPINB1 | OPRM1 4885/4885HTR2A 4769/4885HTR2C 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.